# Walvax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/walvax

- Industry: Biotechnology
- Headquarters: Kunming, China
- Website: www.walvax.com.cn
- Total disclosed funding: $5.1M
- Latest round: Series A (Mar 31, 2008)
- Investors on record: 2

## About

Established in 2001 and based in Kunming, China, Walvax operates as a biotechnology company that mainly provides vaccines and blood products. It has subsidiaries in Shanghai, Beijing, and Yuxi. In 2007, the first product, Haemophilus influenzae type b conjugate vaccine, was launched. In March 2008, Walvax raised CNY 36 million of series A funding from HongTa Venture Capital and Chang'an Capital. In November 2010, the company was listed on the Shenzhen Stock Exchange.

The company mainly provides human vaccine products. Products include non-EPI vaccines (non-EPI) and immunization vaccines (EPI). Non-EPI includes bivalent human papillomavirus vaccine, pneumococcal polysaccharide conjugate vaccine, and Haemophilus influenzae conjugate vaccine. EPI includes group A and group C meningococcal polysaccharide vaccines and adsorbed acellular diphtheria, pertussis and tetanus combined vaccine. Walvax's products under development include nine-valent cervical cancer vaccine, new crown mRNA vaccine, etc. The products are used to prevent bacteremia pneumonia, meningitis, sepsis, bacteremia and other diseases.

The company generates revenue by providing human vaccine products such as non-EPI and EPI.

## Funding rounds

- Series A, Mar 31, 2008, $5.1M — Chang'an Capital, HongTa Venture Capital

## Investors

- Chang'an Capital (https://capitalatlas.ai/funds/chang-an-capital) — Series A
- HongTa Venture Capital — Series A